GAITHERSBURG, Md., Jan. 27 /PRNewswire-FirstCall/ -- Digene Corporation today announced it intends to release fiscal 2006 second quarter results for the three months ended December 31, 2005 at the close of market on Wednesday, February 8, 2006.
Digene will host a conference call, which will be broadcast live over the Internet on Wednesday, February 8, 2006 at 4:30 p.m. E.S.T. The broadcast will be hosted on the Company’s website located at http://www.digene.com.
Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.
The online archive of the broadcast will be available within two hours of the live call and can be accessed through February 22, 2006, by dialing (866) 473-2109 or (203) 369-1498.
About Digene
Digene Corporation , based in Gaithersburg, MD, develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases -- with a focus on women’s cancers and infectious diseases. The company’s hc2 High-Risk HPV DNA Test(R) is the only test for human papillomavirus approved by the FDA, and is approved for both follow-up evaluation in women with inconclusive Pap results and for primary adjunctive screening with the Pap test in women age 30 and older. For primary adjunctive screening, it is marketed as both The Digene HPV Test and the DNAwithPap(TM) Test. These brand names do not refer to the Digene product that tests for several types of the virus commonly referred to as “low-risk HPV,” which are not associated with cervical cancer. For more information, visit http://www.thehpvtest.com. Digene’s product portfolio also includes DNA tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses. For more information, visit the company’s Web site, http://www.digene.com. Investors also may contact Charles Fleischman at (301) 944-7000; journalists may contact Pam Rasmussen, (301) 944-7196.
Digene(R), Hybrid Capture(R) and hc2 High-Risk HPV DNA Test(R) are registered trademarks and DNAwithPap(TM) Test is a trademark of Digene Corporation.
Digene Corporation
CONTACT: Investors: Charles M. Fleischman, President, +1-301-944-7000, ormedia: Pam Rasmussen, +1-301-944-7196, both of Digene Corporation; orInvestors: Jonathan Birt, or Media: Sean Leous, both of Financial Dynamics,+1-212-850-5600, for Digene Corporation
